News & Trends

• 282024-11

  Salubris’innovative drugs Xinliting and FoLitan ® have been included in China's national reimbursement drug list

• 272024-08

  Salubris obtaining the exclusive right of base editing drug YOLT-101

• 052024-08

  The innovative anti-tumor drug JK06 was approved for overseas clinical trial

• 012024-08

  Enarodustat’s new indication approved for clinical trial

• 312024-07

  SAL0120 tablets for treatment of chronic kidney disease(CKD) approved for clinical trial

• 052024-07

  Innovative type 2 diabetes drug Fultagliptin benzoate tablet (Xinliting) obtained marketing authorization